A complete analysis of the common side effects and treatment methods of Pazopanib Tablets (Weiqant)

Pazopanib is an oral multi-target tyrosine kinase inhibitor mainly used to treat advanced renal cell carcinoma (RCC) and certain types of soft tissue sarcomas. Its mechanism of action is mainly through inhibiting vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR) and c-KIT signaling pathways, thereby inhibiting tumor angiogenesis and tumor cell proliferation. Although pazopanib has shown good efficacy in clinical applications, its treatment is often accompanied by certain adverse reactions. Understanding side effects and scientific treatment methods is crucial to improving patients' quality of life and treatment compliance.

Hematologic and systemic symptoms are important manifestations of common side effects of pazopanib. Thrombocytopenia, leukopenia, and anemia may cause patients to experience symptoms such as susceptibility to bleeding, susceptibility to infection, and fatigue. For these situations, doctors usually recommend monitoring blood routine indicators before medication and regularly during treatment. Mild to moderate abnormalities can be treated with rest, nutritional support, and if necessary, erythropoietin or growth factor intervention; for moderate to severe hematological abnormalities, it may be necessary to temporarily discontinue the drug or adjust the dosage to ensure drug safety.

In terms of the digestive system, nausea, vomiting, diarrhea, constipation and loss of appetite are common reactions of patients. Mild symptoms can be relieved by eating small, frequent meals, a light diet, and rehydration; moderate or severe symptoms may require a combination of antiemetics, antidiarrheals, or rehydration. Some patients may also experience stomatitis or dry mouth during use. Keeping the mouth clean, gargling with salt water, or treating with topical medications can effectively reduce discomfort. In addition, long-term medication may lead to abnormal liver function, manifested as an increase in transaminases or bilirubin. Therefore, liver function indicators need to be monitored regularly. Once obvious abnormalities are found, the dosage should be adjusted or the medication should be temporarily discontinued under the guidance of a doctor, and liver protection treatment can be taken.

Cardiovascular system and skin reactions are also side effects of concern during the use of pazopanib. Some patients may develop high blood pressure, edema, or abnormal heart rhythm. High blood pressure is one of the more common side effects and can be controlled by regularly monitoring blood pressure, using antihypertensive drugs, and adjusting lifestyle habits. Cutaneous manifestations include hand-foot syndrome, rash, itching, or hyperpigmentation, and mild symptoms may be relieved by moisturizing, topical medications, or oral allergy medications. For systemic symptoms such as fatigue, headache, or muscle and joint pain, moderate rest, light exercise, and nutritional support can help improve the patient's quality of life.

The principles for scientifically handling the side effects of pazopanib are early detection, early intervention, and individualized management. Patients should establish a self-monitoring system during medication, record weight, blood pressure, skin conditions and any symptoms of discomfort, and review blood, liver and kidney function and imaging indicators on time. Mild and moderate side effects can usually be alleviated through symptomatic treatment and lifestyle adjustments, while side effects that are moderate to severe or affect quality of life require dose adjustment, temporary drug suspension, or adjuvant treatment under the guidance of a doctor. Through standardized management, most of the adverse reactions of pazopanib can be effectively controlled, allowing patients to complete treatment safely and continuously, while improving drug efficacy and overall quality of life.

Reference link:https://www.drugs.com